These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 29285236)

  • 1. Intrapleural targeted therapies (anti-VEGF and anti-EGFR) in the model of malignant pleural effusion.
    Acencio MMP; Puka J; Alvarenga VA; Martins V; de Carvalho MLP; Marchi E; Capelozzi VL; Teixeira LR
    Oncotarget; 2017 Dec; 8(62):105093-105102. PubMed ID: 29285236
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnostic values of vascular endothelial growth factor and epidermal growth factor receptor for benign and malignant hydrothorax.
    Gu Y; Zhang M; Li GH; Gao JZ; Guo L; Qiao XJ; Wang LH; He L; Wang ML; Yan L; Fu XH
    Chin Med J (Engl); 2015 Feb; 128(3):305-9. PubMed ID: 25635424
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EGFR and KRAS mutations in lung carcinomas in the Dutch population: increased EGFR mutation frequency in malignant pleural effusion of lung adenocarcinoma.
    Smits AJ; Kummer JA; Hinrichs JW; Herder GJ; Scheidel-Jacobse KC; Jiwa NM; Ruijter TE; Nooijen PT; Looijen-Salamon MG; Ligtenberg MJ; Thunnissen FB; Heideman DA; de Weger RA; Vink A
    Cell Oncol (Dordr); 2012 Jun; 35(3):189-96. PubMed ID: 22528563
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EGFR mutations predict a favorable outcome for malignant pleural effusion of lung adenocarcinoma with Tarceva therapy.
    Guo H; Wan Y; Tian G; Liu Q; Kang Y; Li Y; Yao Z; Lin D
    Oncol Rep; 2012 Mar; 27(3):880-90. PubMed ID: 22134479
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized clinical study to compare intrapleural infusion with intravenous infusion of bevacizumab in the management of malignant pleural effusion in patients with non-small-cell lung cancer.
    Nie K; Zhang Z; You Y; Zhuang X; Zhang C; Ji Y
    Thorac Cancer; 2020 Jan; 11(1):8-14. PubMed ID: 31726490
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intrapleural combination therapy with bevacizumab and cisplatin for non-small cell lung cancer‑mediated malignant pleural effusion.
    Du N; Li X; Li F; Zhao H; Fan Z; Ma J; Fu Y; Kang H
    Oncol Rep; 2013 Jun; 29(6):2332-40. PubMed ID: 23525453
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The efficacy of pemetrexed and bevacizumab intrapleural injection for malignant pleural mesothelioma-mediated malignant pleural effusion.
    Chen D; Li X; Zhao H; Fu Y; Yao F; Hu J; Du N
    Indian J Cancer; 2014 Mar; 51 Suppl 3():e82-5. PubMed ID: 25818740
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EGFR mutation status in primary lung adenocarcinomas and corresponding metastatic lesions: discordance in pleural metastases.
    Han HS; Eom DW; Kim JH; Kim KH; Shin HM; An JY; Lee KM; Choe KH; Lee KH; Kim ST; Koo JH; Lee HC; Lee OJ
    Clin Lung Cancer; 2011 Nov; 12(6):380-6. PubMed ID: 21729655
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of EGFR mutation rates in lung adenocarcinoma tissue and pleural effusion samples.
    Guan Y; Wang ZJ; Wang LQ; Hua DF; Liu J
    Genet Mol Res; 2016 Apr; 15(2):. PubMed ID: 27173189
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Carboplatin and cisplatin pharmacokinetics after intrapleural combination treatment in patients with malignant pleural effusion.
    Lerza R; Vannozzi MO; Tolino G; Viale M; Bottino GB; Bogliolo G; Cerruti A; Castello G; Mencoboni M; Reggiardo G; Pannacciulli I; Esposito M
    Ann Oncol; 1997 Apr; 8(4):385-91. PubMed ID: 9209670
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Yield of Malignant Pleural Effusion for Detection of Oncogenic Driver Mutations in Lung Adenocarcinoma.
    DeMaio A; Clarke JM; Dash R; Sebastian S; Wahidi MM; Shofer SL; Cheng GZ; Li X; Wang X; Mahmood K
    J Bronchology Interv Pulmonol; 2019 Apr; 26(2):96-101. PubMed ID: 30048416
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intrapleural or intraperitoneal lobaplatin for treatment of patients with malignant pleural effusion or ascites.
    Huang XE; Wei GL; Huo JG; Wang XN; Lu YY; Wu XY; Liu J; Xiang J; Feng JF
    Asian Pac J Cancer Prev; 2013; 14(4):2611-4. PubMed ID: 23725184
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A sulindac analogue is effective against malignant pleural effusion in mice.
    Moschos C; Psallidas I; Cottin T; Kollintza A; Papiris S; Roussos C; Stathopoulos GT; Giannis A; Kalomenidis I
    Lung Cancer; 2011 Aug; 73(2):171-5. PubMed ID: 21227533
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effect of anti-vascular endothelial growth factor antibody on pleurodesis induced by transforming growth factor-beta or doxycycline in rabbits].
    Guo YB; Xie CM; Light RW
    Zhonghua Jie He He Hu Xi Za Zhi; 2006 Jan; 29(1):39-43. PubMed ID: 16638300
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monoclonal anti-vascular endothelial growth factor antibody reduces fluid volume in an experimental model of inflammatory pleural effusion.
    Ribeiro SC; Vargas FS; Antonangelo L; Marchi E; Genofre EH; Acencio MM; Teixeira LR
    Respirology; 2009 Nov; 14(8):1188-93. PubMed ID: 19818055
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A central role for tumor-derived monocyte chemoattractant protein-1 in malignant pleural effusion.
    Stathopoulos GT; Psallidas I; Moustaki A; Moschos C; Kollintza A; Karabela S; Porfyridis I; Vassiliou S; Karatza M; Zhou Z; Joo M; Blackwell TS; Roussos C; Graf D; Kalomenidis I
    J Natl Cancer Inst; 2008 Oct; 100(20):1464-76. PubMed ID: 18840818
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I clinical and pharmacological study of liposome-entrapped NDDP administered intrapleurally in patients with malignant pleural effusions.
    Perez-Soler R; Shin DM; Siddik ZH; Murphy WK; Huber M; Lee SJ; Khokhar AR; Hong WK
    Clin Cancer Res; 1997 Mar; 3(3):373-9. PubMed ID: 9815694
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A modified experimental model of malignant pleural disease induced by lung Lewis carcinoma (LLC) cells.
    Acencio MM; Puka J; Marchi E; Antonangelo L; Terra RM; Vargas FS; Capelozzi VL; Teixeira LR
    J Transl Med; 2015 Sep; 13():302. PubMed ID: 26373420
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of PNA clamping and direct sequencing for detecting KRAS mutations in matched tumour tissue, cell block, pleural effusion and serum from patients with malignant pleural effusion.
    Kang JY; Park CK; Yeo CD; Lee HY; Rhee CK; Kim SJ; Kim SC; Kim YK; Park MS; Yim HW
    Respirology; 2015 Jan; 20(1):138-46. PubMed ID: 25302858
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CT Radiogenomic Characterization of EGFR, K-RAS, and ALK Mutations in Non-Small Cell Lung Cancer.
    Rizzo S; Petrella F; Buscarino V; De Maria F; Raimondi S; Barberis M; Fumagalli C; Spitaleri G; Rampinelli C; De Marinis F; Spaggiari L; Bellomi M
    Eur Radiol; 2016 Jan; 26(1):32-42. PubMed ID: 25956936
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.